{"id":"W2795150236","doi":"10.2217/fon-2018-0121","title":"Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Celgene; Sanofi; Genentech; Ariad Pharmaceuticals; Amgen","keywords":"Venetoclax; Medicine; Clinical trial; Refractory (planetary science); Oncology; Internal medicine; Drug development; Chronic lymphocytic leukemia; Chemotherapy; Cancer; Drug; Leukemia; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00120617,0.0001987876,0.0006129741,0.0004835558,0.00005566327,0.000006589269,0.0002236838,0.0002157349,0.0001773267],"category_scores_gemma":[0.0002326879,0.0001737872,0.00003377618,0.0007892459,0.0001115192,0.00005568104,0.0001390193,0.0004479092,0.00002017352],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02193918,"about_ca_system_score_gemma":0.03192395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001271013,"about_ca_topic_score_gemma":0.004896155,"domain_scores_codex":[0.9977221,0.0002212224,0.0007051741,0.000421199,0.0004013403,0.0005289494],"domain_scores_gemma":[0.9988522,0.0003291037,0.0002027132,0.0002967517,0.0002021657,0.0001170701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02843801,0.03889183,0.3072578,0.002845262,0.0006840225,0.006648735,0.2872058,0.002066146,0.1160149,0.0003617849,0.02043066,0.1891551],"study_design_scores_gemma":[0.5678964,0.03589468,0.2487631,0.001164238,0.0004529454,0.0005036509,0.02965404,0.02052747,0.03428456,0.00006213223,0.05902417,0.001772636],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959479,0.00113446,0.00007485264,0.0002110458,0.000470319,0.00150178,0.000002914062,0.00002275884,0.0006339901],"genre_scores_gemma":[0.9929671,0.0001720689,0.004804692,0.000153952,0.001221497,0.0003384243,0.000005538974,0.00003079092,0.0003059063],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5394584,"threshold_uncertainty_score":0.9818154,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06121352229830328,"score_gpt":0.3801271580229051,"score_spread":0.3189136357246018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}